See the abstract from our oral presentation at #AACR24 on an exploratory analysis of a phase 3 study accessing the efficacy of PARPi + androgen receptor inhibitor in pts w/ metastatic castration-resistant #ProstateCancer w/ or w/o HRR mutations CT018 bit.ly/3IU6exb
0
0
0
560
0
Download Image